Patents by Inventor Margit Wissenbach
Margit Wissenbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120322848Abstract: The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5?-(MeCx)(Tx)MeCxAsAstsCsCsastsgsgsMeCxAx(Gx)(c)-3?, and preferably of the general formula 5?-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3?, wherein capital letters designate an LNA nucleotide analogue selected from ?-D-oxy-LNA, ?-D-thio-LNA, ?-D-amino-LNA and ?-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumour development in vivo.Type: ApplicationFiled: April 10, 2012Publication date: December 20, 2012Applicant: Santaris Pharma A/SInventors: Christoph Rosenbohm, Lene S. Kjaerulff, Majken Westergaard, Margit Wissenbach, Jens B. Hansen, Marlene Asklund
-
Patent number: 8173428Abstract: The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5?-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx(Gx)(c)-3?, and preferably of the general formula 5?-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3?, wherein capital letters designate an LNA nucleotide analogue selected from ?-D-oxy-LNA, ?-D-thio-LNA, ?-D-amino-LNA and ?-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumor development in vivo.Type: GrantFiled: October 10, 2008Date of Patent: May 8, 2012Assignees: Santaris Pharma A/S, Enzon Pharmaceuticals, Inc.Inventors: Christoph Rosenbohm, Lene Sonderbye Kjaerulff, Majken Westergaard, Margit Wissenbach, Jens Bo Hansen, Marlene Asklund
-
Publication number: 20120088907Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.Type: ApplicationFiled: July 14, 2011Publication date: April 12, 2012Applicants: Santaris Pharma A/S, Enzon PharmaceuticalsInventors: Bo Hansen, Charlotte Albaek Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
-
Patent number: 8026355Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.Type: GrantFiled: April 22, 2010Date of Patent: September 27, 2011Assignees: Santaris Pharma A/S, Enzon Pharmaceuticals, Inc.Inventors: Jens Bo Rode Hansen, Charlotte Albaek Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
-
Publication number: 20100292311Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.Type: ApplicationFiled: April 22, 2010Publication date: November 18, 2010Applicants: Enzon Pharmaceuticals, Santaris Pharma A/SInventors: Bo Hansen, Charlotte Albaek Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
-
Patent number: 7741309Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.Type: GrantFiled: June 29, 2009Date of Patent: June 22, 2010Assignees: Santaris Pharma A/SInventors: Jens Bo Rode Hansen, Charlotte Albaek Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
-
Patent number: 7713738Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.Type: GrantFiled: February 10, 2004Date of Patent: May 11, 2010Assignees: Santaris Pharma A/SInventors: Bo Hansen, Charlotte Albæk Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
-
Publication number: 20090318362Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.Type: ApplicationFiled: June 29, 2009Publication date: December 24, 2009Inventors: Jens Bo rode Hansen, Charlotte Albaek Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
-
Publication number: 20090181914Abstract: The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5?-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx)(Gx)(c)-3?, and preferably of the general formula 5?-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3?, wherein capital letters designate an LNA nucleotide analogue selected from ?-D-oxy-LNA, ?-D-thio-LNA, ?-D-amino-LNA and ?-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumour development in vivo.Type: ApplicationFiled: October 10, 2008Publication date: July 16, 2009Applicants: SANTARIS PHARMA A/S, ENZON PHARMACEUTICALS, INC.Inventors: CHRISTOPH ROSENBOHM, LENE S. KJAERULFF, MAJKEN WESTERGAARD, MARGIT WISSENBACH, JENS B. HANSEN, MARLENE ASKLUND
-
Publication number: 20080188432Abstract: Oligonucleotides directed against the Ha-ras gene are provided for modulating the expression of Ha-ras. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the Ha-ras. Methods of using these compounds for modulation of Ha-ras expression and for the treatment of diseases associated with either overexpression of Ha-ras, expression of mutated Ha-ras or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.Type: ApplicationFiled: December 15, 2006Publication date: August 7, 2008Inventors: Bo Hansen, Charlotte Albaek Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
-
Publication number: 20060154888Abstract: The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5?-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx(Gx)(c)-3?, and preferably of the general formula 5?-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3?, wherein capital letters designate an LNA nucleotide analogue selected from ?-D-oxy-LNA, ?-D-thio-LNA, ?-D-amino-LNA and ?-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumour development in vivo.Type: ApplicationFiled: November 9, 2005Publication date: July 13, 2006Applicant: Santaris Pharma A/SInventors: Christoph Rosenbohm, Lene Kjaerulff, Majken Westergaard, Margit Wissenbach, Jens Hansen, Marlene Asklund
-
Publication number: 20050014712Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.Type: ApplicationFiled: February 10, 2004Publication date: January 20, 2005Inventors: Bo Hansen, Charlotte Thrue, Majken Westergaard, Kamille Petersen, Margit Wissenbach
-
Publication number: 20040248840Abstract: Oligonucleotides directed against the Ha-ras gene are provided for modulating the expression of Ha-ras. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the Ha-ras. Methods of using these compounds for modulation of Ha-ras expression and for the treatment of diseases associated with either overexpression of Ha-ras, expression of mutated Ha-ras or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.Type: ApplicationFiled: February 10, 2004Publication date: December 9, 2004Applicant: Santaris Pharma A/SInventors: Bo Hansen, Charlotte Albaek Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
-
Publication number: 20040241717Abstract: Oligonucleotides directed against the TRX gene are provided for modulating the expression of TRX. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the TRX. Methods of using these compounds for modulation of TRX expression and for the treatment of diseases associated with either overexpression of TRX, expression of mutated TRX or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.Type: ApplicationFiled: February 10, 2004Publication date: December 2, 2004Applicant: Santaris Pharma A/SInventors: Bo Hansen, Charlotte Albaek Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
-
Publication number: 20030199431Abstract: The present invention relates to novel drugs which may be used in combating infectious micro-organisms, particularly bacteria.Type: ApplicationFiled: March 27, 2002Publication date: October 23, 2003Inventors: Peter E. Nielsen, Liam Good, Henrik Frydenlund Hansen, Frederik Beck, Leila Malik, Carsten Schou, Margit Wissenbach, Birgit Kjaeldgaard Giwercman
-
Publication number: 20030176325Abstract: The present invention relates to novel drugs which may be used in combating infectious micro-organisms, particularly bacteria.Type: ApplicationFiled: October 19, 2001Publication date: September 18, 2003Applicant: Pantheco A/S and Peter E. NielsenInventors: Peter E. Nielsen, Liam Good, Henrik Frydenlund Hansen, Frederik Beck, Leila Malik, Carsten Schou, Margit Wissenbach, Birgit Kjaeldgaard Giwercman
-
Publication number: 20030125241Abstract: The invention relates to therapeutic applications of LNA-modified oligonucleotides. In particular, the invention provides methods for treatment of infectious diseases and disorders caused by viruses, bacteria, protozoa or fungi. Preferably, administration of an LNA-modified oligonucleotide modulates expression of a targeted gene associated with the replication or infectivity of a virus, virulence genes, host immune modulating genes and the like. That is, preferred use of LNA-modified oligonucleotide provides an antisense-type therapy with selective modulation of gene expression of predetermined targets.Type: ApplicationFiled: May 17, 2002Publication date: July 3, 2003Inventors: Margit Wissenbach, Troels Koch, Henrik Orum, Bo Hansen
-
Patent number: 6548651Abstract: The present invention relates to novel drugs which may be used in combating infectious micro-organisms, particularly bacteria. More specifically, the invention relates to peptide nucleic acid (PNA) sequences that are modified by conjugating cationic peptides to the PNA moiety in order to obtain novel PNA molecules that exhibit enhanced anti-infective properties.Type: GrantFiled: October 12, 2000Date of Patent: April 15, 2003Assignees: Pantheco A/SInventors: Peter E. Nielsen, Liam Good, Henrik Frydenlund Hansen, Frederik Beck, Leila Malik, Carsten Schou, Margit Wissenbach, Birgit Kjaeldgaard Giwercman